Researchers Identified Compound That Blocks KSHV Replication
A flavonoid derivative targets host enzymes to stop the virus from replicating in human cells.
Updated on Sept. 21, 2026 in Life Sciences
Researchers have identified icariside I as a potent inhibitor of Kaposi's sarcoma-associated herpesvirus (KSHV) lytic replication. This research, published in a report, highlights how the compound interferes with the virus's ability to propagate within host cells.
Why it matters
KSHV is responsible for serious malignancies including Kaposi's sarcoma and primary effusion lymphoma, yet current clinical options remain limited. This finding identifies a specific host enzyme target that could eventually lead to new therapeutic strategies for these conditions.
Icariside I inhibits KSHV by binding to the host enzyme amidophosphoribosyltransferase at residues Glu124 and Asp389. This interaction disrupts de novo purine synthesis, a pathway the virus requires for replication, which can be bypassed by supplementing with hypoxanthine.
The players
KSHV
A human herpesvirus known to cause malignancies such as Kaposi's sarcoma and primary effusion lymphoma.
The details
The team utilized drug affinity and surface plasmon resonance—a method for measuring molecular binding in real-time—to confirm that icariside I binds directly to amidophosphoribosyltransferase. By targeting this host enzyme, the compound effectively starves the virus of purines, which are essential building blocks for viral DNA. The mechanism specifically hinges on the interaction with Glu124 and Asp389, effectively shutting down the KSHV lytic cycle.
Timeline
September 21, 2026: The research findings were officially published.
The Tech Race
This research follows a growing pattern of antiviral studies focusing on host-dependency factors rather than viral targets to prevent drug resistance. It advances the search for small-molecule inhibitors in a field currently constrained by a lack of effective treatments for KSHV-associated cancers.
This research is currently at the laboratory stage and does not offer immediate medical treatments for the public. Future development will focus on determining whether this mechanism can be safely translated into a pharmacological therapy for patients.
The takeaway
This discovery demonstrates that targeting host-specific enzymes like amidophosphoribosyltransferase can effectively halt viral replication. Watch for future studies evaluating the compound in clinical models or trials to assess its potential as a therapeutic agent.
Further reading
For more on the latest research in viral suppression, visit Life Sciences.
Source note: This article includes information reported by Nature.
